Round Type
Series C
Description
Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors. Concurrent with the financing, Nanna Lüneborg from Novo Ventures, Matthias Fehr from HBM Partners, and Carlo Incerti from Forbion have been appointed to Numab’s Board of Directors.
Quick answer
Numab Therapeutics raised an undisclosed amount in a Series C round, dated May 20, 2021.
- How much did Numab Therapeutics raise?
- Numab Therapeutics raised an undisclosed amount in a Series C round on May 20, 2021.
- What does Numab Therapeutics do?
- Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer.
- Where is Numab Therapeutics based and how big is it?
- Fundz records about 68 employees.
- Who are the decision-makers at Numab Therapeutics?
- Fundz holds 1 contact at Numab Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Numab Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Synaptogenix raised $12M on June 29, 2021.
- Arbutus raised $81M on June 23, 2021.
- TRex Bio raised $59M (Series A) on June 22, 2021.
- Zevra Therapeutics, Inc. raised $39M on June 22, 2021.
- OncoNano Medicine raised $50M (Series B) on June 17, 2021.
- Korsana Biosciences raised $18M on June 17, 2021.
Who to call at Numab Therapeutics, and when
A new round usually means Numab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Numab Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Numab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Numab Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Numab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Numab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.